Modified hyperinsulinaemic, eu- and hypoglycaemic clamp technique using lispro-insulin for insulinoma diagnostic

Summary:

Characterization of metabolically inadequate insulin secretion is essential for insulinoma diagnostics. Hyperinsulinaemic, eu- and hypoglycaemic clamp procedures have been used to suppress endogenous insulin secretion in healthy subjects. The use of exogenous insulin precluded the use of insulin as a parameter to be measured. We now suggest to use exogenous insulin lispro and an insulin-specific ELISA not cross reacting with insulin lispro. Thus, determination of insulin by ELISA in this experimental setting reflects endogenous insulin. A 39-year-old man with a surgically confirmed pancreatic insulinoma was studied under hyperinsulinaemic [lispro insulin 40 mU · m^-2 body surface ·min^-1] clamp conditions. Euglycaemia was achieved (3.8 ± 0.5 mmol/L) for 1 h and hypoglycaemia (2.36 ± 0.49 mmol/L) was achieved for another 30 min. Insulin was evaluated by ELISA (cross-reaction with lispro insulin < 0.006%, C-peptide < 0.01%, proinsulin < 0.001%) and by a nonselective RIA (cross-reaction with proinsulin 40%). In control subjects the euglycaemic hyperinsulinaemia suppressed C-peptide to 0.36 ± 0.03 ng/ml and hypoglycaemic hyperinsulinaemia to 0.29 ± 0.03 ng/ml. Endogenous insulin was suppressed to 2.8 ± 0.03 mU/L under euglycaemia and to 2.6 ± 0.03 mU/L under hypoglycaemia in control subjects. In the insulinoma patient apparently irregular but small changes in both C-peptide (1.43 ± 0.1 ng/ml) and more pronounced changes in endogenous insulin concentrations 4.41 ± 0.1 mU/l under euglycaemia and 5.35 ± 0.3 mU/l under hypoglycaemic conditions, were observed. The basal level of insulin (ELISA insulin 4.6 mU/L) and C-peptide (1.7 ng/ml) were not markedly elevated. Determination of insulin allowed better characterization of irregular pulses because of the shorter half-life of insulin relative to C-peptide. The new modification of sequential eu- and hypoglycaemic clamp procedures should also be useful in pharmacological studies of insulinotropic substances. Direct measurement of peripheral insulin may be more sensitive than C-peptide to detect low levels of autonomous insulin secretion in small insulinomas.

Key words:

Insulinoma diagnostic - insulin analogue - hypoglycaemic clamp

References

• 1 Berman N, Genter P, Chou H F, Bowsher R, Ipp E. Erratic oscillatory characteristics of plasma insulin concentration in patients with insulinoma: mechanism for unpredictable hypoglycaemia.  J Clin Endocrinol Metab. 82 2899-2903 1997; 
• 2 Bowsher R R, Lynch R A, Broun-Augsburger P, Santa P F, Legan W E, Woodworth J R, Chance R E. Sensitive RIA for the specific determination of lispro insulin.  Clin Chem. 45 104-110 1999; 
• 3 Clark H E, Matthews R. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperglycaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.  Horm Metab Res. 28 445-450 1996; 
• 4 Cohen P, Barzilai N, Bar-Ilan R, Yasin K, Karnieli E. Lack of suppression of insulin secretion by hyperinsulinaemia in a patient with an insulinoma.  J Clin Endocrinol Metab. 63 1411-1413 1986; 
• 5 De Fronzo R A, Tobin J D, Anders R. Glucose clamp technique: a method for quantifying insulin secretion and resistance.  Am J Physiol (Endocrinol Metab). 273 E214-E223 1979; 
• 6 Faber O K, Hagen C, Binder C. Kinetics of human connecting peptide in normal and diabetic subjects.  J Clin Invest. 62 197-203 1978; 
• 7 Jarhult J, Ericsson M, Holst J, Ingemansson S. Lack of suppression of insulin secretion by exercise in patients with insulinoma.  Clin Endocrinol (Oxf). 15 391-393 1981; 
• 8 Kao P C, Taylor R L, Service F J. Proinsulin by immunnohemiluminometric assay for the diagnosis of insulinoma.  J Clin Endocrinol Metab. 78 1048-1051 1994; 
• 9 Nankervis A, Proietto J, Aitken P, Alford F. Hyperinsulinaemia and insulin insensitivity: studies in subjects with insulinoma.  Diabetologia. 28 427-431 1990; 
• 10 Nauck M A, Stöckmann F, Creutzfeldt W. Evaluation of a euglycaemic clamp procedure as a diagnostic test in insulinoma patients.  Eur J Clin Invest. 20 15-28 1990; 
• 11 Nauck M A, Baum F, Seidenstricker F, Røder M, Dinesen B, Creutzfeldt W. A hyperinsulinaemic, sequentially eu- and hypoglycaemic clamp test to characterize autonomous insulin secretion in patients with insulinoma.  Europ J Clin Invest. 27 109-115 1997; 
• 12 Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J. Hierarchy of glycaemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction.  Am J Physiol (Endocrinol Metab). 260 E67-E64 1991; 
• 13 Rubenstein A H, Block M B, Starr J, Melani F, Steiner D F. Proinsulin and C-peptide in blood.  Diabetes. 21 661-672 1972; 
• 14 Rudowitsch N, Nauck M A, Dick D, Schatz H, Pfeiffer A FH. Modified hyperinsulinaemic, eu- and hypoglycaemic clamp technique using lyspro-insulin for insulinoma diagnostic.  Exp Clin Endocrinol Diabetes ((Supplement 1)) 108 S146 2000; 
• 15 Schwartz N S, Clutter W E, Shah S D, Cryer P E. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the thresholds for symptoms.  J Clin Invest. 79 777 1987; 
• 16 Service F J, O'Brien P C, Kao P C, Young W F. C-peptide suppression test: effects of gender, age, and body mass index; implications for the diagnosis of insulinoma.  J Clin Endocrinol Metab. 74 204-210 1992; 
• 17 Service F J, O'Brien P C, McMahon M, Kao P C. C-peptide during the prolonged fast in insulinoma.  J Clin Endocrinol Metab. 76 655-659 1993; 
• 18 Turner R C, Oakley N W, Nabarro J DN. Control of basal insulin secretion, with special reference to the diagnosis of insulinomas.  Br Med J. 2 132-135 1971; 
• 19 Yki-Jarvinen H, Pelkonen R, Koivisto V A. Failure to suppress C-peptide secretion by euglycaemic hyperinsulinaemia: a new diagnostic test for insulinoma?.  Clin Endocrinol (Oxf). 23 461-466 1985;